Ginkgo Bioworks Holdings Inc. (DNA): Find Out What Insiders Are Doing


Ginkgo Bioworks Holdings Inc. (NYSE:DNA) finished Thursday with an addition of $0.02 to close at $1.67, an upside of 1.21 percent. An average of 18,532,619 shares of common stock have been traded in the last five days. There was a fall of -$0.0800 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 22,627,240 shares traded, while the 50-day average volume stands at 24,850,844.

DNA stock has decreased by -9.73% in the last month. The company shares reached their 1-month lowest point of $1.5700 on 12/16/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $1.57 and a high of $9.34 in 52 weeks. It has reached a new high 1 time so far this year and lost -79.90% or -$6.6400 in price. In spite of this, the price is down -82.12% from the 52-week high.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Insider Transactions

DNA stock investors should be aware that Ginkgo Bioworks Holdings Inc. (DNA) stock had its last reported insider trading activity 7 days ago on Dec 23. In this transaction, the insider spent $334,306. 10% Owner, Canton Barry, disposed of 203,349 shares at a price of $1.64 on Dec 23. The insider now owns more than $334,306 worth of shares. Prior to that, Shetty Reshma P. went on to Sale 203,349 shares at $1.64 each on Dec 23. An amount of $334,306 was transacted.

Valuation Metrics

Ginkgo Bioworks Holdings Inc. (DNA) has a trailing price-to-sales (P/S) ratio at 4.90, the price-to-book (PB) ratio at 1.90.

Financial Health

The quick ratio of Ginkgo Bioworks Holdings Inc. for the three months ended September 29 was 11.70, and the current ratio was 11.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.04 and a total debt to equity ratio of 0.04 for the quarter ending September 29. Its gross profit as reported stood at $184.15 million compared to revenue of $313.84 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Ginkgo Bioworks Holdings Inc.’s return on assets was -176.60%.

Earnings Surprise

The analyst consensus anticipated Ginkgo Bioworks Holdings Inc.’s latest quarter earnings to come in at -$0.3 per share, but it turned out to be -$0.41, a -36.70% surprise. For the quarter, EBITDA amounted to -$643.51 million. Shareholders own equity worth $1.74 billion.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Ginkgo Bioworks Holdings Inc. (DNA) price momentum. RSI 9-day as of the close on 29 December was 40.69%, suggesting the stock is Neutral, with historical volatility in this time frame at 54.34%.

As of today, DNA’s price is $1.6680 -4.57% or -$0.0800 from its 5-day moving average. DNA is currently trading -16.08% lower than its 20-day SMA and -48.46% lower than its 100-day SMA. However, the stock’s current price level is -37.22% below the SMA50 and -42.61% below the SMA200.

The stochastic %K and %D were 22.48% and 22.22%, respectively, and the average true range (ATR) was 0.1372. With the 14-day stochastic at 23.26% and the average true range at 0.1526, the RSI (14) stands at 39.19%. The stock has reached -0.0189 on the 9-day MACD Oscillator while the 14-day reading was at -0.0419.

Analyst Ratings

Berenberg launched coverage on Ginkgo Bioworks Holdings Inc. (NYSE: DNA) in its analyst report released on November 29, 2022. The firm assigned the stock a Buy rating. The consensus rating for Ginkgo Bioworks Holdings Inc. (DNA) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell DNA, while 2 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 5 others rate it as a “buy”.

What is DNA’s price target for the next 12 months?

Analysts predict a range of price targets between $3.00 and $12.00, with a median target of $4.00. Taking a look at these predictions, the average price target given by analysts for Ginkgo Bioworks Holdings Inc. (DNA) stock is $5.05.


Please enter your comment!
Please enter your name here